India has achieved a historic milestone as Wockhardt's novel antibiotic ZAYNICH (cefepime + zidebactam) received US FDA approval – the first new chemical entity fully discovered and developed by an Indian company to get this clearance. This breakthrough offers safer options against multidrug-resistant Gram-negative infections, directly addressing the global antimicrobial resistance (AMR) crisis. For exam aspirants, this is a high-yield topic linking science, health policy, and India's pharma ecosystem.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drug Name: ZAYNICH™ (cefepime and zidebactam)
- ›Developer: Wockhardt Ltd.
- ›Target this Data: US FDA approval date – May 30, 2026; DCGI approval – May 27, 2026.
- ›Target this Drug: ZAYNICH (cefepime + zidebactam) – first Indian-developed US FDA-approved antibiotic.
- ›Target this Nodal Body: Drugs Controller General of India (DCGI) and US Food and Drug Administration (FDA).
- ›Target this Location: Research centre in Chhatrapati Sambhajinagar, Maharashtra (earlier Aurangabad).
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.